CD86 and neoplasm: They all have their own ligand on APC (such as CD80, CD86 for CTLA-4 or PD-L1 and PD-L2 for PD-1), and tumor cells, depending on tumor types, may substitute them, thus using this immune checkpoint machinery to avoid cell killing.